Drug shortages in Canada, 2019-2023: A descriptive study.

IF 1 Q4 PHARMACOLOGY & PHARMACY

Annales pharmaceutiques francaises Pub Date : 2024-12-05 DOI:10.1016/j.pharma.2024.12.001

Ilona Béatrix, Elsa Bonnabry, Suzanne Atkinson, Denis Lebel, Jean-François Bussières

{"title":"Drug shortages in Canada, 2019-2023: A descriptive study.","authors":"Ilona Béatrix, Elsa Bonnabry, Suzanne Atkinson, Denis Lebel, Jean-François Bussières","doi":"10.1016/j.pharma.2024.12.001","DOIUrl":null,"url":null,"abstract":"Context: Drug shortages impact patients from all countries. According to the Pharmaceutical Group of the European Union, most Europe countries reported a worsening of shortages in 2023.Objective: To describe drug shortage episodes in Canada over a recent 4-year period.Methods: This study focused on drug shortage episodes over the 52-month period from September 1, 2019, to December 31, 2023. Two data sources were used: the Canadian mandatory reporting website (both community and hospital settings) and hospital wholesaler data. Only descriptive statistical analyses were performed.Results: From September 1, 2019, to December 31, 2023, a total of 10,975 drug shortage episodes and 1087 discontinuations were reported on the Canadian website, whereas 2562 drug shortage episodes were reported by the hospital wholesaler. The median duration of episodes was 51days according to reports at the Canadian website data versus 145days according to the wholesaler's data. The Canadian website data referred to a total of 184 manufacturers, whereas wholesaler data encompassed 83 manufacturers. Only 86 episodes were rated as Tier 3.Conclusions: This study highlights the high number of drug shortages in Canada in recent years, both in the overall market and in the hospital market. Although the median duration of episodes has decreased across the country, the number of manufacturers involved has increased. The danger lies in considering the current situation as inevitable, normal and persistent.","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales pharmaceutiques francaises","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pharma.2024.12.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Context: Drug shortages impact patients from all countries. According to the Pharmaceutical Group of the European Union, most Europe countries reported a worsening of shortages in 2023.

Objective: To describe drug shortage episodes in Canada over a recent 4-year period.

Methods: This study focused on drug shortage episodes over the 52-month period from September 1, 2019, to December 31, 2023. Two data sources were used: the Canadian mandatory reporting website (both community and hospital settings) and hospital wholesaler data. Only descriptive statistical analyses were performed.

Results: From September 1, 2019, to December 31, 2023, a total of 10,975 drug shortage episodes and 1087 discontinuations were reported on the Canadian website, whereas 2562 drug shortage episodes were reported by the hospital wholesaler. The median duration of episodes was 51days according to reports at the Canadian website data versus 145days according to the wholesaler's data. The Canadian website data referred to a total of 184 manufacturers, whereas wholesaler data encompassed 83 manufacturers. Only 86 episodes were rated as Tier 3.

Conclusions: This study highlights the high number of drug shortages in Canada in recent years, both in the overall market and in the hospital market. Although the median duration of episodes has decreased across the country, the number of manufacturers involved has increased. The danger lies in considering the current situation as inevitable, normal and persistent.

查看原文本刊更多论文

2019-2023年加拿大药品短缺：一项描述性研究

背景：药物短缺影响着所有国家的患者。据欧盟制药集团（Pharmaceutical Group of European Union）称，大多数欧洲国家报告称，2023年药品短缺将加剧。目的：描述近4年来加拿大药品短缺事件。方法：本研究重点关注2019年9月1日至2023年12月31日52个月期间的药品短缺事件。使用了两个数据来源：加拿大强制性报告网站（社区和医院设置）和医院批发商数据。仅进行描述性统计分析。结果：2019年9月1日至2023年12月31日，加拿大网站共报告了10975起药品短缺事件和1087起停药事件，而医院批发商报告了2562起药品短缺事件。根据加拿大网站数据的报告，发作的中位持续时间为51天，而根据批发商的数据为145天。加拿大网站的数据涉及184家制造商，而批发商的数据包括83家制造商。只有86集被评为三级。结论：这项研究突出了近年来加拿大的药品短缺问题，无论是在整体市场还是在医院市场。尽管全国范围内的平均发作时间有所减少，但涉及的制造商数量却有所增加。危险在于认为目前的情况是不可避免的、正常的和持续的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annales pharmaceutiques francaises PHARMACOLOGY & PHARMACY-

CiteScore

1.70

自引率

7.70%

发文量

期刊介绍： This journal proposes a scientific information validated and indexed to be informed about the last research works in all the domains interesting the pharmacy. The original works, general reviews, the focusing, the brief notes, subjected by the best academics and the professionals, propose a synthetic approach of the last progress accomplished in the concerned sectors. The thematic Sessions and the – life of the Academy – resume the communications which, presented in front of the national Academy of pharmacy, are in the heart of the current events.